INNATE PHARMA

Société Anonyme

117, avenue de Luminy BP 30191 13276 Marseille Cedex 9

Statutory Auditors' report prepared in accordance with Article L. 225-235 of the French Commercial Code (*Code de commerce*) on the report prepared by the Chairman of the Supervisory Board

Year ended 31 December 2015

Audit Conseil Expertise SAS

Membre de PKF International 17, boulevard Augustin Cieussa 13007 Marseille

Deloitte & Associés

Les Docks – Atrium 10.4 10, place de la Joliette 13002 Marseille

INNATE PHARMA

Société Anonyme
117, avenue de Luminy
BP 30191
13276 Marseille Cedex 9

Statutory Auditors' report prepared in accordance with Article L. 225-235 of the French Commercial Code (*Code de commerce*) on the report prepared by the Chairman of the Supervisory Board

Year ended 31 December 2015

This is a free translation into English of the statutory auditors' report issued in French prepared in accordance with Article L.225-235 of the French Commercial Code on the report prepared by the Chairman of the Supervisory Board on the internal control and risk management procedures relating to the preparation and processing of the accounting and financial information issued in French and is provided solely for the convenience of English speaking users.

This report should be read in conjunction and construed in accordance with French law and the relevant professional standards applicable in France.

To the Shareholders,

In our capacity as Statutory Auditors of Innate Pharma and in accordance with Article L. 225-235 of the French Commercial Code (*Code de commerce*), we hereby report to you on the report prepared by the Chairman of your Company in accordance with Article L. 225-68 of the French Commercial Code for the year ended 31 December 2015.

It is the Chairman's responsibility to prepare, and submit to the Supervisory Board for approval, a report on the internal control and risk management procedures implemented by the Company and containing the other disclosures required by Article L. 225-68 of the French Commercial Code, particularly in terms of corporate governance.

INNATE PHARMA 2/3

It is our responsibility:

- to report to you on the information contained in the Chairman's report in respect of the internal control and risk management procedures relating to the preparation and processing of the accounting and financial information; and

- to attest that this report contains the other disclosures required by Article L. 225-68 of the French Commercial Code, it being specified that we are not responsible for verifying the fairness of these disclosures.

We conducted our work in accordance with professional standards applicable in France.

Information on the internal control and risk management procedures relating to the preparation and processing of the accounting and financial information

Professional standards require that we perform the necessary procedures to assess the fairness of the information provided in the Chairman's report in respect of the internal control and risk management procedures relating to the preparation and processing of the accounting and financial information. These procedures mainly consisted in:

- obtaining an understanding of the internal control and risk management procedures relating to the preparation and processing of the accounting and financial information on which the information presented in the Chairman's report is based and the existing documentation;
- obtaining an understanding of the work involved in the preparation of this information and the existing documentation;
- determining if any significant weaknesses in the internal control procedures relating to the
 preparation and processing of the accounting and financial information that we would
 have noted in the course of our engagement are properly disclosed in the Chairman's
 report.

On the basis of our work, we have nothing to report on the information in respect of the Company's internal control and risk management procedures relating to the preparation and processing of the accounting and financial information contained in the report prepared by the Chairman of the Supervisory Board in accordance with Article L. 225-68 of the French Commercial Code.

Other disclosures

We hereby attest that the report prepared by the Chairman of the Supervisory Board includes the other disclosures required by Article L. 225-68 of the French Commercial Code.

INNATE PHARMA 3/3

Marseille, 18 April 2016 The Statutory Auditors

Audit Conseil Expertise SAS Member of PKF International Deloitte & Associés

Nicolas Lehnertz

Hugues Desgranges